If your patients take any of our medicines but cannot afford them, AstraZeneca may be able to help
If you would like additional information regarding AstraZeneca products, please contact the Information Center at AstraZeneca in the US at 1-800-236-9933, Monday through Friday, 8:00 am to 6:00 pm ET, excluding holidays.
WARNING: ISCHEMIC HEART DISEASE
Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered TOPROL-XL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1–2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, TOPROL-XL administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Warn patients against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue TOPROL-XL therapy abruptly even in patients treated only for hypertension.
Click here for full Prescribing Information, including boxed warning regarding abrupt cessation of therapy.
This product information is intended for US health care professionals only.
Generic metoprolol succinate extended-release tablets are manufactured for Par Pharmaceutical Company, Inc., Spring Valley, NY, by AstraZeneca AB, Södertälje, Sweden.
Toprol-XL is a registered trademark and AZ&Me is a trademark of the AstraZeneca group of companies.
©2010 AstraZeneca. All rights reserved. 1195903 5/11